Various treatment options under investigation for the treatment of progressive multiple sclerosis.
The staff neurologist at the Mellen Center shared the findings from a poster the group presented from the cohort of patients in which they evaluated quantitative MRI.
The staff neurologist at Cleveland Clinic's Mellen Center spoke about the real-world observational study of the primary-progressive MS treatment.
The staff neurologist at Cleveland Clinic's Mellen Center spoke about re-examining patient-reported outcomes to better understand the quality of life of patients and how it can affect clinical care.
The Andrew & Erna Viterbi Professor of Electrical Engineering and Computer Science at MIT spoke about a new way of continuous monitoring for patients with MS and neurodegenerative disorders, discovering changes in quality of life and new biomarkers.
The expert panelists share prominent take-home messages and discuss where they believe the field of epilepsy management will head in upcoming years.
The director of the probabilistic vision group and medical imaging lab at McGill University spoke about how these learning methods can be used to predict future lesion activity and disability progression in MS.
Expert clinicians remark on the significance of the recent approval of ocrelizumab for primary progressive multiple sclerosis and discuss the potential of siponimod for secondary progressive MS.
SAP Partner Banner